Today, we announced a leadership transition at Legend Biotech.

We thank Ying Huang, Ph.D., for his leadership and many contributions over the past seven years, helping to transform Legend into a global leader in cell therapy and laying a strong foundation for the future.

Congratulations to Alan Bash on his appointment as Interim CEO. As a valued member of the Legend leadership team, Alan will continue to guide the company as we remain focused on executing our strategy, advancing our commercial and clinical priorities, expanding our pipeline, and bringing innovative cell therapies to more patients around the world.

Read more: https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-announces-ceo-transition

#LegendBiotech #CellTherapy #Innovation